Search

Your search keyword '"Fielding AK"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Fielding AK" Remove constraint Author: "Fielding AK"
122 results on '"Fielding AK"'

Search Results

1. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia.

2. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

5. Standardized MRD quantification in European ALL trials: proceedings of the second international symposium on MRD assessment in Kiel, Germany, 18-20 September 2008

6. (2002) Strength of Envelope Protein Interaction Modulates Cytopathicity of Measles Virus

7. Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts.

9. Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

11. A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study.

13. Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia.

15. Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.

16. Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials.

18. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.

19. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.

20. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study.

22. Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL.

23. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial.

24. Single nucleotide polymorphism array-based signature of low hypodiploidy in acute lymphoblastic leukemia.

25. Utility of 18F-FDG-PET/CT in lymphoblastic lymphoma.

26. Acute lymphoblastic leukaemia (ALL) things come to those who wait: 60 years of progress in the treatment of adult ALL.

28. Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO.

29. CD1a is rarely expressed in pediatric or adult relapsed/refractory T-ALL: implications for immunotherapy.

30. Quality-of-life issues and symptoms reported by patients living with haematological malignancy: a qualitative study.

31. Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.

32. Successful remission induction therapy with gilteritinib in a patient with de novo FLT3-mutated acute myeloid leukaemia and severe COVID-19.

33. Monitoring MRD in ALL: Methodologies, technical aspects and optimal time points for measurement.

34. Type 1 Interferon Responses Underlie Tumor-Selective Replication of Oncolytic Measles Virus.

35. Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.

37. Curing Ph+ ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant.

38. Activated stromal cells transfer mitochondria to rescue acute lymphoblastic leukemia cells from oxidative stress.

39. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

41. Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia.

42. Paper and electronic versions of HM-PRO, a novel patient-reported outcome measure for hematology: an equivalence study.

43. Blinatumomab, a bispecific B-cell and T-cell engaging antibody, in the treatment of B-cell malignancies.

44. Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia.

45. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.

46. ARF way to Ph + ALL stratification?

47. The evolving role of chemotherapy and hematopoietic cell transplants in Ph-positive acute lymphoblastic leukemia in adults.

48. Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.

49. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study.

50. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.

Catalog

Books, media, physical & digital resources